 |
We are advised by Antengene Corporation Limited that journalists and other readers should disregard the news release, Antengene Announces XPOVIO® Approved in China for the Second-Line Treatment of Multiple Myeloma, Marking the Third Approved Indication of the Drug, issued 28-Jul-2025 over PR Newswire.
source: Antengene Corporation Limited
【你點睇？】兩名顧客光顧火鍋放題店疑企圖帶走食材，你認為二人是否需要負上更多責任？► 立即投票
